BSc III - T2 Biosystms CEO President

TTOO Stock  USD 0.49  0.02  3.92%   

CEO

BSc III is CEO President of T2 Biosystms
Age 61
Address 101 Hartwell Avenue, Lexington, MA, United States, 02421
Phone781 761 4646
Webhttps://www.t2biosystems.com

T2 Biosystms Management Efficiency

The company has return on total asset (ROA) of (0.9046) % which means that it has lost $0.9046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.2214) %, meaning that it created substantial loss on money invested by shareholders. T2 Biosystms' management efficiency ratios could be used to measure how well T2 Biosystms manages its routine affairs as well as how well it operates its assets and liabilities. At this time, T2 Biosystms' Return On Capital Employed is very stable compared to the past year. As of the 26th of November 2024, Return On Equity is likely to grow to 1.88, while Return On Tangible Assets are likely to drop (1.51). At this time, T2 Biosystms' Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Current Assets Total is likely to grow to about 11.6 M, while Non Currrent Assets Other are likely to drop about 345.7 K.
T2 Biosystms currently holds 49.5 M in liabilities with Debt to Equity (D/E) ratio of 6.64, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. T2 Biosystms has a current ratio of 1.83, which is within standard range for the sector. Note, when we think about T2 Biosystms' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 4 records

CEO Age

Eric MBASeres Therapeutics
48
Joseph MBAMilestone Pharmaceuticals
56
John TuckerScpharmaceuticals
61
BAO BChEliem Therapeutics
48
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. T2 Biosystems operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 182 people. T2 Biosystms (TTOO) is traded on NASDAQ Exchange in USA. It is located in 101 Hartwell Avenue, Lexington, MA, United States, 02421 and employs 113 people. T2 Biosystms is listed under Biotechnology category by Fama And French industry classification.

Management Performance

T2 Biosystms Leadership Team

Elected by the shareholders, the T2 Biosystms' board of directors comprises two types of representatives: T2 Biosystms inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TTOO. The board's role is to monitor T2 Biosystms' management team and ensure that shareholders' interests are well served. T2 Biosystms' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, T2 Biosystms' outside directors are responsible for providing unbiased perspectives on the board's policies.
Roger Smith, Senior Development
Aparna MD, Chief Board
Kelley Morgan, Chief Officer
BSc III, CEO President
Michael Esq, Sr Counsel
Brett Giffin, Chief Officer
Alec Barclay, Senior Vice President - Operations
John CPA, Chief Officer

TTOO Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is T2 Biosystms a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with T2 Biosystms

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if T2 Biosystms position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in T2 Biosystms will appreciate offsetting losses from the drop in the long position's value.

Moving together with TTOO Stock

  0.77ME 23Andme HoldingPairCorr
  0.92VALN Valneva SE ADRPairCorr
  0.77JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr

Moving against TTOO Stock

  0.61KZR Kezar Life SciencesPairCorr
  0.52MLYS Mineralys Therapeutics,PairCorr
  0.5MDGL Madrigal PharmaceuticalsPairCorr
  0.38NXGLW NexGel WarrantPairCorr
  0.37RNXT RenovoRxPairCorr
The ability to find closely correlated positions to T2 Biosystms could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace T2 Biosystms when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back T2 Biosystms - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling T2 Biosystms to buy it.
The correlation of T2 Biosystms is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as T2 Biosystms moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if T2 Biosystms moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for T2 Biosystms can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether T2 Biosystms offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of T2 Biosystms' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of T2 Biosystms Stock. Outlined below are crucial reports that will aid in making a well-informed decision on T2 Biosystms Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.03)
Revenue Per Share
0.999
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.90)
Return On Equity
(6.22)
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.